-
-
-
-
-
-
-
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
-
-
-
-
-
-
-
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
-
15,631 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

